Paper36044544
2-(Fluoromethoxy)-4'-(S-methanesulfonimidoyl)-1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson's Disease.
García-Cárceles J and 14 others. J Med Chem, 2022. Cited by 7 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. 2-(Fluoromethoxy)-4'-(S-methanesulfonimidoyl)-1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson's Disease. Papers, record 36044544. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36044544
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- 2-(Fluoromethoxy)-4'-(S-methanesulfonimidoyl)-1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson's Disease.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cocaine | Major topic |
| Parkinson Disease | Major topic |
| Animals | |
| Biphenyl Compounds | |
| Dopamine | |
| Dopamine Agents | |
| Dopamine Agonists | |
| Humans | |
| Indazoles | |
| Levodopa | |
| Ligands | |
| Mice | |
| Nitrofurans | |
| Receptors, Dopamine | |
| Receptors, Dopamine D1 |
Source PubMed
References63
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15,116,359 | Development and testing of a general amber force field. | J Comput Chem | 2004 | https://conductscience.org/library/papers/15116359 | PubMed |
| 2 | 27,900,648 | Etelcalcetide: First Global Approval. | Drugs | 2016 | https://conductscience.org/library/papers/27900648 | PubMed |
| 3 | 25,176,435 | Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. | Nat Rev Drug Discov | 2014 | https://conductscience.org/library/papers/25176435 | PubMed |
| 4 | 22,148,748 | Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. | J Med Chem | 2012 | https://conductscience.org/library/papers/22148748 | PubMed |
| 5 | 25,076,876 | Distinct motor impairments of dopamine D1 and D2 receptor knockout mice revealed by three types of motor behavior. | Front Integr Neurosci | 2014 | https://conductscience.org/library/papers/25076876 | PubMed |
| 6 | 16,229,044 | Vanadium-catalyzed sulfur oxidation/kinetic resolution in the synthesis of enantiomerically pure alkyl aryl sulfoxides. | Angew Chem Int Ed Engl | 2005 | https://conductscience.org/library/papers/16229044 | PubMed |
| 7 | 29,075,003 | Trends in GPCR drug discovery: new agents, targets and indications. | Nat Rev Drug Discov | 2017 | https://conductscience.org/library/papers/29075003 | PubMed |
| 8 | 23,398,684 | Regulation of G protein-coupled receptors by allosteric ligands. | ACS Chem Neurosci | 2013 | https://conductscience.org/library/papers/23398684 | PubMed |
| 9 | 15,742,468 | Investigations on the iron-catalyzed asymmetric sulfide oxidation. | Chemistry | 2005 | https://conductscience.org/library/papers/15742468 | PubMed |
| 10 | 21,548,569 | Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid. | J Med Chem | 2011 | https://conductscience.org/library/papers/21548569 | PubMed |
| 11 | 30,111,649 | Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor. | Mol Pharmacol | 2018 | https://conductscience.org/library/papers/30111649 | PubMed |
| 12 | 28,280,503 | New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease. | Front Biol (Beijing) | 2015 | https://conductscience.org/library/papers/28280503 | PubMed |
| 13 | 25,671,228 | Dopamine receptors - IUPHAR Review 13. | Br J Pharmacol | 2015 | https://conductscience.org/library/papers/25671228 | PubMed |
| 14 | 23,319,549 | The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. | Pharmacol Rev | 2013 | https://conductscience.org/library/papers/23319549 | PubMed |
| 15 | 24,634,647 | Effects of acute versus repeated cocaine exposure on the expression of endocannabinoid signaling-related proteins in the mouse cerebellum. | Front Integr Neurosci | 2014 | https://conductscience.org/library/papers/24634647 | PubMed |
| 16 | 9,857,974 | Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. | Mol Psychiatry | 1998 | https://conductscience.org/library/papers/9857974 | PubMed |
| 17 | 26,100,627 | Novel Allosteric Modulators of G Protein-coupled Receptors. | J Biol Chem | 2015 | https://conductscience.org/library/papers/26100627 | PubMed |
| 18 | 9,482,355 | Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. | Arch Neurol | 1998 | https://conductscience.org/library/papers/9482355 | PubMed |
| 19 | 24,111,540 | Drugs for allosteric sites on receptors. | Annu Rev Pharmacol Toxicol | 2014 | https://conductscience.org/library/papers/24111540 | PubMed |
| 20 | 27,148,592 | Allosteric Modulation of G Protein-Coupled Receptors: An Emerging Approach of Drug Discovery. | Austin J Pharmacol Ther | 2014 | https://conductscience.org/library/papers/27148592 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,387,961 | Asymmetric synthesis of stereogenic-at-sulfur compounds via biocatalytic oxidation with Unspecific Peroxygenases. | Nat Commun | 2025 | https://conductscience.org/library/papers/41387961 | PubMed |
| 40,308,780 | Ginsenoside Rg1 in Parkinson's disease: from basic research to clinical applications. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40308780 | PubMed |
| 38,931,832 | Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now? | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38931832 | PubMed |
| 38,238,465 | Asymmetric synthesis of sulfoximines, sulfonimidoyl fluorides and sulfonimidamides enabled by an enantiopure bifunctional S(VI) reagent. | Nat Chem | 2024 | https://conductscience.org/library/papers/38238465 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36044544
GET https://conductscience.org/api/papers/v1/36044544/references?page=2